OCGN•benzinga•
Ocugen Announced That The European Medicines Agency Has Granted Orphan Medicinal Product Designation For OCU410ST For The Treatment Of Abca4-associated Retinopathies Including Stargardt Disease, Retinitis Pigmentosa 19, And Cone-rod Dystrophy 3
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga